We are live on ! Find out more
OI

Oakbrook Investments Portfolio holdings

AUM $39.2M
1-Year Est. Return 3.66%
This Fund
S&P 500
This Quarter Est. Return
+8.78%
1 Year Est. Return
-3.66%
3 Year Est. Return
+26.09%
5 Year Est. Return
+53.43%
10 Year Est. Return
AUM
$1.8B
AUM Growth
+$220M
Cap. Flow
+$92.2M
Cap. Flow %
5.11%
Top 10 Hldgs %
23.35%
Holding
698
New
144
Increased
374
Reduced
112
Closed
60

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$23.4M
2
V icon
Visa
V
+$13.3M
3
ADSK icon
Autodesk
ADSK
+$10.2M
4
PEP icon
PepsiCo
PEP
+$9.62M
5
ORCL icon
Oracle
ORCL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 17.33%
2 Technology 16.65%
3 Financials 15.24%
4 Consumer Discretionary 11.43%
5 Industrials 11.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAPL icon
1
Apple
AAPL
$4.67T
$63.6M 3.53%
1,126,504
-58,056
-5% -$3.02M
NKE icon
2
Nike
NKE
$58.7B
$43.9M 2.44%
518,760
+17,149
+3% +$1.38M
MDT icon
3
Medtronic
MDT
$117B
$41.8M 2.32%
425,135
-24,421
-5% -$2.26M
V icon
4
Visa
V
$712B
$41.1M 2.28%
274,098
-93,259
-25% -$13.3M
ADSK icon
5
Autodesk
ADSK
$55B
$40.3M 2.24%
258,309
-72,245
-22% -$10.2M
MRK icon
6
Merck
MRK
$366B
$40M 2.22%
590,442
-36,016
-6% -$2.29M
CAT icon
7
Caterpillar
CAT
$368B
$39.6M 2.2%
259,798
-15,669
-6% -$2.22M
DIS icon
8
Walt Disney
DIS
$187B
$39.6M 2.2%
338,690
-16,817
-5% -$1.87M
AMGN icon
9
Amgen
AMGN
$234B
$35.5M 1.97%
171,426
-30,363
-15% -$5.98M
CME icon
10
CME Group
CME
$103B
$35.5M 1.97%
208,565
-12,433
-6% -$2.09M
MSFT icon
11
Microsoft
MSFT
$3.81T
$35.2M 1.95%
307,622
+400
+0.1% +$43.4K
GOOGL icon
12
Alphabet (Google) Class A
GOOGL
$4.24T
$35M 1.94%
580,200
+7,000
+1% +$424K
SBUX icon
13
Starbucks
SBUX
$123B
$34.6M 1.92%
608,265
-35,849
-6% -$1.9M
AMZN icon
14
Amazon
AMZN
$2.87T
$33.9M 1.88%
338,580
-13,500
-4% -$1.27M
MKC icon
15
McCormick & Company Non-Voting
MKC
$14.9B
$32.6M 1.81%
494,718
-30,100
-6% -$1.86M
VAR
16
DELISTED
Varian Medical Systems, Inc.
VAR
$31.5M 1.75%
281,196
-49,852
-15% -$5.64M
PEP icon
17
PepsiCo
PEP
$193B
$30.6M 1.7%
273,976
-84,946
-24% -$9.62M
MMM icon
18
3M
MMM
$89.9B
$26.4M 1.46%
149,732
-30,113
-17% -$5.19M
QCOM icon
19
Qualcomm
QCOM
$175B
$24.7M 1.37%
343,306
-24,150
-7% -$1.59M
GOOG icon
20
Alphabet (Google) Class C
GOOG
$4.19T
$23.4M 1.3%
392,920
-28,580
-7% -$1.71M
CL icon
21
Colgate-Palmolive
CL
$72.3B
$23.2M 1.28%
+345,909
New +$23M
SLB icon
22
SLB Ltd
SLB
$85.1B
$21.2M 1.17%
347,474
-27,596
-7% -$1.78M
JCI icon
23
Johnson Controls International
JCI
$84.6B
$19.3M 1.07%
552,632
-33,203
-6% -$1.22M
META icon
24
Meta Platforms (Facebook)
META
$1.47T
$17.5M 0.97%
106,642
+2,150
+2% +$389K
BIIB icon
25
Biogen
BIIB
$32.3B
$17.4M 0.97%
49,305
+1,374
+3% +$473K

Similar funds

Oakbrook Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Oakbrook Investments held 698 positions worth $1.8B, up 14% from $1.58B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Oakbrook Investments deployed $92.2M of net new capital in Q3 2018, opening 144 new positions and adding to 374 existing holdings. Its largest new stake was Colgate-Palmolive: 345,909 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Gilead Sciences, an estimated $23.4M trimmed.

  • Oakbrook Investments's largest Q3 2018 buy was Colgate-Palmolive: 345,909 shares worth $23.2M.
  • Oakbrook Investments added most to Mondelez International in Q3 2018, an estimated $11.8M increase.
  • Oakbrook Investments's biggest Q3 2018 reduction was Gilead Sciences, cutting an estimated $23.4M.
  • Oakbrook Investments fully exited CSX Corp in Q3 2018, selling an estimated $3.83M.
  • Oakbrook Investments's ten largest holdings make up 23% of its $1.8B portfolio in Q3 2018.
  • Oakbrook Investments opened 144 new positions and closed 60 in Q3 2018.
  • Oakbrook Investments's portfolio value rose 14% quarter-over-quarter to $1.8B.

Based on Oakbrook Investments's 13F filing for Q3 2018, filed 18 Oct 2018.